Innovent Biologics (SEHK:1801) Valuation Check After 40% Product Revenue Growth and Mazdutide Milestone

Simply Wall St.

Nov 03

Innovent Biologics (SEHK:1801) just reported a 40% jump in product revenue for the third quarter, fueled by strong growth in both its established oncology portfolio as well as newer offerings like ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2580232806"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580232806\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580232806?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2025-11-03 01:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580232806","market":"hk","top_or_hot":-1,"title":"Innovent Biologics (SEHK:1801) Valuation Check After 40% Product Revenue Growth and Mazdutide Milestone","media":"Simply Wall St.","content":"<div>\n<p>Innovent Biologics (SEHK:1801) just reported a 40% jump in product revenue for the third quarter, fueled by strong growth in both its established oncology portfolio as well as newer offerings like ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/innovent-biologics-sehk1801-valuation-check-after-40-product\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent Biologics (SEHK:1801) Valuation Check After 40% Product Revenue Growth and Mazdutide Milestone</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent Biologics (SEHK:1801) Valuation Check After 40% Product Revenue Growth and Mazdutide Milestone\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-03 01:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/innovent-biologics-sehk1801-valuation-check-after-40-product><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Innovent Biologics (SEHK:1801) just reported a 40% jump in product revenue for the third quarter, fueled by strong growth in both its established oncology portfolio as well as newer offerings like ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/innovent-biologics-sehk1801-valuation-check-after-40-product\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2097828714.EUR","symbol_name":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/innovent-biologics-sehk1801-valuation-check-after-40-product","article_id":"2580232806","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/innovent-biologics-sehk1801-valuation-check-after-40-product","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2580232806","pubTimestamp":1762104064,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Innovent Biologics (SEHK:1801) just reported a 40% jump in product revenue for the third quarter, fueled by strong growth in both its established oncology portfolio as well as newer offerings like mazdutide and SINTBILO.\nSee our latest analysis for Innovent Biologics.\nInnovent’s shares have been on a rollercoaster in recent weeks, but momentum is clearly building overall. The stock’s 1-year total shareholder return sits at an impressive 148%, even after some profit-taking since last month...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","BK1161":"生物科技","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","01801":"信达生物","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1583":"高瓴概念","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","BK1589":"北水核心资产"},"translate_title":"信达生物（SEHK：1801）产品收入增长40%和Mazdutide里程碑后的估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":0.9,"DCF":1},"content_text":"Innovent Biologics (SEHK:1801) just reported a 40% jump in product revenue for the third quarter, fueled by strong growth in both its established oncology portfolio as well as newer offerings like mazdutide and SINTBILO. See our latest analysis for Innovent Biologics. Innovent’s shares have been on a rollercoaster in recent weeks, but momentum is clearly building overall. The stock’s 1-year total shareholder return sits at an impressive 148%, even after some profit-taking since last month. Excitement around soaring product revenue, breakthrough Phase 3 data for mazdutide, and a blockbuster partnership with Takeda are fueling investor optimism, despite near-term share price swings. If Innovent’s strong run caught your attention, it could be the perfect moment to see what else is gaining traction and check out See the full list for free. But with shares up nearly 150% over the past year and optimism running high, is Innovent Biologics still an undervalued growth play? Or has the market already priced in its future success? AdvertisementPrice-to-Earnings of 120.6x: Is it justified? Innovent Biologics trades at a price-to-earnings (P/E) ratio of 120.6x, which directly reflects investor optimism and lofty growth expectations baked into the current share price of HK$87. The P/E ratio shows how much investors are willing to pay for each dollar of earnings. In the biotech sector, high multiples can signal a powerful growth story but also reflect elevated risk if those future earnings do not materialize. However, Innovent's P/E stands massively above the Asian Biotechs industry average of just 43.7x and the peer average of 42x. The stock's P/E is also more than triple the estimated fair P/E ratio of 35.4x. This suggests the market has pushed the valuation well beyond longer-term earnings fundamentals. Explore the SWS fair ratio for Innovent Biologics Result: Price-to-Earnings of 120.6x (OVERVALUED) However, risks remain if future earnings growth disappoints, or if competitive pressures in the biotech sector begin to weigh more heavily on profit margins. Find out about the key risks to this Innovent Biologics narrative. Another View: SWS DCF Model Suggests Value Upside While the market’s P/E ratio points to Innovent Biologics being overvalued, our SWS DCF model tells a different story. The model estimates a fair value of HK$104.15 versus the current share price of HK$87, implying the stock is actually trading 16.5% below its intrinsic value. Look into how the SWS DCF model arrives at its fair value. 1801 Discounted Cash Flow as at Nov 2025This sharp divergence between earnings multiples and intrinsic valuation leaves investors with a critical question: are long-term cash flow projections more reliable than the sentiment-driven P/E ratio? The answer could influence the next move for Innovent’s share price. Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Innovent Biologics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 840 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own Innovent Biologics Narrative If you want to see the data from another angle or trust your independent research, you can easily build your own story in minutes. Do it your way A good starting point is our analysis highlighting 4 key rewards investors are optimistic about regarding Innovent Biologics. Looking for More Winning Investment Opportunities? Don’t miss your chance to seize the next big breakthrough. Powerful investment themes are thriving beyond Innovent, and you could be on the front line.  Spot companies harnessing the power of artificial intelligence and shape your portfolio with these 26 AI penny stocks before the crowd catches on. Secure steady income by reviewing these 22 dividend stocks with yields > 3% featuring reliable yield from proven performers in today's market. Capitalize on innovation, growth, and volatility by identifying these 3590 penny stocks with strong financials positioned for explosive potential that most investors overlook.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}